Literature DB >> 10759657

Nonhomologous bioinjectable materials in urology: 'size matters'?

L Z Solomon1, B R Birch, A J Cooper, C L Davies, S A Holmes.   

Abstract

OBJECTIVE: To assess the factors that influence how particles might become fixed in tissues or migrate from them, by measuring the size of the injectable particles, their susceptibility to phagocytosis and their affinity for fibroblast attachment in culture.
MATERIALS AND METHODS: The particle size of three types of particulate unphysiological bioinjectable material, i.e. Urocol (Genesis Medical, Ltd., London), Macroplastiquetrade mark (Uroplasty Ltd., Reading, UK) and Urethrin (Mentor Medical Systems, Wantage, UK) was analysed using phase-contrast light microscopy and confocal microscopy. Human monocytes from peripheral blood were incubated with the three materials in phagocytic studies, where ingestion was determined by confocal microscopy. A fibroblast cell line was used to ascertain the ability of the particles to act as a substrate for cell attachment in culture.
RESULTS: The mean (SEM) maximum particle diameters of Macroplastique, Urethrin and Urocol were 209 (5.10) microm, 49 (1.52) microm and 14 (0.39) microm, respectively. Rat peritoneal macrophages and human peripheral blood monocytes commonly ingested Urocol particles; the phagocytosis of Urethrin was rare and that of Macroplastique was not detected. Fibroblasts adhered to Urocol paste and Urethrin particles, but not to Macroplastique.
CONCLUSION: Published reports of particle size and phagocytosis are confusing, but a relationship clearly exists. Macroplastique is the largest particle and is least likely to be phagocytosed by human mononuclear phagocytes. Urocol paste is the slowest to dissipate in culture conditions; the flat surfaces of Urethrin, but not Macroplastique, can serve as a substrate for fibroblast anchorage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10759657     DOI: 10.1046/j.1464-410x.2000.00521.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

1.  Effect of the Macroplastique Implantation System for stress urinary incontinence in women with or without a history of an anti-incontinence operation.

Authors:  Ilknur Inegol Gumus; Ikbal Kaygusuz; Aysel Derbent; Serap Simavli; Hasan Kafali
Journal:  Int Urogynecol J       Date:  2011-04-02       Impact factor: 2.894

2.  Effects of Macroplastique Implantation System for stress urinary incontinence and urethral hypermobility in women.

Authors:  Ph H ter Meulen; L C M Berghmans; F H M Nieman; Ph E V A van Kerrebroeck
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-10-21

3.  Endoscopic treatment of vesicoureteral reflux in pediatric patients.

Authors:  Jong Wook Kim; Mi Mi Oh
Journal:  Korean J Pediatr       Date:  2013-04-22

4.  Local giant cell foreign body reaction after silicone injection for fecal incontinence in humans: two case reports.

Authors:  B van Wunnik; A Driessen; C Baeten
Journal:  Tech Coloproctol       Date:  2011-06-22       Impact factor: 3.781

Review 5.  Emerging periurethral bulking agents for female stress urinary incontinence: is new necessarily better?

Authors:  Jonathan S Starkman; Harriette Scarpero; Roger R Dmochowski
Journal:  Curr Urol Rep       Date:  2006-09       Impact factor: 2.862

Review 6.  Endoscopic injection therapy.

Authors:  Sang Woon Kim; Yong Seung Lee; Sang Won Han
Journal:  Investig Clin Urol       Date:  2017-06-02

Review 7.  Brazilian consensus on vesicoureteral reflux-recommendations for clinical practice.

Authors:  José Murillo Bastos; Atila Victal Rondon; Marcos Giannetti Machado; Miguel Zerati; Rodrigo Lessa Pena Nascimento; Salvador Vilar Correa Lima; Adriano de Almeida Calado; Ubirajara Barroso
Journal:  Int Braz J Urol       Date:  2020 Jul-Aug       Impact factor: 1.541

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.